Search - tctmd.com

Displaying 521 - 540 of 2210

Sort: Relevancy | Date

Real-world Data Show MitraClip Benefit in COAPT-Ineligible Patients

Michael O'Riordan

November 17, 2019

News Conference News AHA 2019

Early Surgery Beats a Conservative Approach in Asymptomatic AS: RECOVERY

Yael L. Maxwell

November 16, 2019

News Daily News

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Michael O'Riordan

November 06, 2019

News Industry News

Edwards SAPIEN 3 TAVI Receives Expanded Approval In Europe

November 06, 2019

News Daily News

Gaps in Access to TAVR and SAVR: ‘Something Needs to Be Done’

L.A. McKeown

October 29, 2019

News Daily News

New-Onset A-fib Tied to Particularly Poor Outcomes After TAVR

Todd Neale

October 18, 2019

News Daily News

Risk Prediction Model Personalizes Revascularization Options for FREEDOM-Like Patients

Michael O'Riordan

October 17, 2019

News Industry News

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

October 09, 2019

News Daily News

PARTNER 2A at EACTS 2019: ‘The Message Is Exactly the Same’

Shelley Wood

October 08, 2019

News Daily News

Interventional Options and Future Directions for Acute PE: New AHA Statement

Todd Neale

October 07, 2019

News Conference News TCT 2019

Predicting Final Valve Position After TAVR: Different Devices, Different Success

Michael O'Riordan

October 07, 2019

News Conference News TCT 2019

MitraClip Pricey but ‘Acceptable’ in COAPT Cost-Efficacy Analysis

Shelley Wood

September 29, 2019

News Conference News TCT 2019

TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3

Yael L. Maxwell

September 29, 2019

News Conference News TCT 2019

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

Todd Neale

September 29, 2019

News Conference News TCT 2019

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

Michael O'Riordan

September 29, 2019

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

News Conference News TCT 2019

Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis

Michael O'Riordan

September 27, 2019

News Conference News TCT 2019

Portico Noninferior to Commercial TAVR Valves in IDE Study

Caitlin E. Cox

September 27, 2019

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

News Conference News TCT 2019

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

Michael O'Riordan

September 27, 2019

Advertisement

Real-world Data Show MitraClip Benefit in COAPT-Ineligible Patients

Early Surgery Beats a Conservative Approach in Asymptomatic AS: RECOVERY

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Edwards SAPIEN 3 TAVI Receives Expanded Approval In Europe

Gaps in Access to TAVR and SAVR: ‘Something Needs to Be Done’

New-Onset A-fib Tied to Particularly Poor Outcomes After TAVR

Risk Prediction Model Personalizes Revascularization Options for FREEDOM-Like Patients

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

PARTNER 2A at EACTS 2019: ‘The Message Is Exactly the Same’

Interventional Options and Future Directions for Acute PE: New AHA Statement

Predicting Final Valve Position After TAVR: Different Devices, Different Success

MitraClip Pricey but ‘Acceptable’ in COAPT Cost-Efficacy Analysis

TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis

Portico Noninferior to Commercial TAVR Valves in IDE Study

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content